Comparative Pharmacology
Head-to-head clinical analysis: ATORVASTATIN CALCIUM versus CRESTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATORVASTATIN CALCIUM versus CRESTOR.
ATORVASTATIN CALCIUM vs CRESTOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol.
10-80 mg orally once daily, starting at 10-20 mg; maximum dose 80 mg/day.
Oral, 5-40 mg once daily. Initial dose typically 10-20 mg; max 40 mg.
None Documented
None Documented
Terminal elimination half-life: 14 hours (range 11–24 h); the active metabolite half-life is 20–30 h; clinical context: supports once-daily dosing despite shorter HMG-CoA reductase inhibitory half-life due to prolonged pharmacodynamic effect.
The terminal elimination half-life is approximately 19 hours (range 13–20 hours). This long half-life allows once-daily dosing and provides sustained HMG-CoA reductase inhibition.
Primarily biliary excretion (approx. 70%) as metabolites; renal excretion accounts for <2% of the administered dose; fecal elimination of metabolites and parent drug (approx. 90%).
Approximately 90% of rosuvastatin is eliminated in feces (as unchanged drug and metabolites), and about 10% is excreted in urine (mainly as unchanged drug). Biliary excretion is the primary route for elimination of metabolites.
Category C
Category C
Statin
Statin